Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance
Reference number: TA284
Published: 22 May 2013

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document

Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): final appraisal determination document
25 March 2013
(291.3 Kb 24 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 22 March 2013